Tillmanns T - Search Results

1

Predictors of complications after inguinal lymphadenectomy.

Gould N, Kamelle S, Tillmanns T, Scribner D, Gold M, Walker J, Mannel R. Gould N, et al. Among authors: tillmanns t. Gynecol Oncol. 2001 Aug;82(2):329-32. doi: 10.1006/gyno.2001.6266. Gynecol Oncol. 2001. PMID: 11531288

2

A retrospective analysis of radical hysterectomies done for cervical cancer: is there a role for the Pfannenstiel incision?

Scribner DR Jr, Kamelle SA, Gould N, Tillmanns T, Wilson MA, McMeekin S, Gold MA, Mannel RS. Scribner DR Jr, et al. Among authors: tillmanns t. Gynecol Oncol. 2001 Jun;81(3):481-4. doi: 10.1006/gyno.2001.6193. Gynecol Oncol. 2001. PMID: 11371142

3

Nodal distribution and its significance in FIGO stage IIIc endometrial cancer.

McMeekin DS, Lashbrook D, Gold M, Scribner DR, Kamelle S, Tillmanns TD, Mannel R. McMeekin DS, et al. Among authors: tillmanns td. Gynecol Oncol. 2001 Aug;82(2):375-9. doi: 10.1006/gyno.2001.6278. Gynecol Oncol. 2001. PMID: 11531298

4

Panniculectomy with simultaneous gynecologic oncology surgery.

Tillmanns TD, Kamelle SA, Abudayyeh I, McMeekin SD, Gold MA, Korkos TG, Johnson PR. Tillmanns TD, et al. Gynecol Oncol. 2001 Dec;83(3):518-22. doi: 10.1006/gyno.2001.6414. Gynecol Oncol. 2001. PMID: 11733965

5

Ovarian cancer metastatic to the brain: what is the optimal management?

McMeekin DS, Kamelle SA, Vasilev SA, Tillmanns TD, Gould NS, Scribner DR, Gold MA, Guruswamy S, Mannel RS. McMeekin DS, et al. Among authors: tillmanns td. J Surg Oncol. 2001 Nov;78(3):194-200; discussion 200-1. doi: 10.1002/jso.1149. J Surg Oncol. 2001. PMID: 11745806 Review.

6

Impact of individual physicians on enrollment of patients into clinical trials.

Mannel RS, Walker JL, Gould N, Scribner DR Jr, Kamelle S, Tillmanns T, McMeekin DS, Gold MA. Mannel RS, et al. Among authors: tillmanns t. Am J Clin Oncol. 2003 Apr;26(2):171-3. doi: 10.1097/00000421-200304000-00014. Am J Clin Oncol. 2003. PMID: 12714890

7

Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?

Kamelle SA, Rutledge TL, Tillmanns TD, Gould NS, Cohn DE, Wright J, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. Kamelle SA, et al. Gynecol Oncol. 2004 Aug;94(2):249-55. doi: 10.1016/j.ygyno.2004.05.038. Gynecol Oncol. 2004. PMID: 15297159

8

A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?

Rutledge TL, Kamelle SA, Tillmanns TD, Gould NS, Wright JD, Cohn DE, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. Rutledge TL, et al. Gynecol Oncol. 2004 Oct;95(1):70-6. doi: 10.1016/j.ygyno.2004.07.027. Gynecol Oncol. 2004. PMID: 15385112

9

Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.

McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J, Mannel R. McMeekin DS, et al. Among authors: tillmanns t. Gynecol Oncol. 2004 Oct;95(1):157-64. doi: 10.1016/j.ygyno.2004.07.008. Gynecol Oncol. 2004. PMID: 15385126

10

Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53.

Tillmanns TD, Kamelle SA, Guruswamy S, Gould NS, Rutledge TL, Benbrook DM. Tillmanns TD, et al. Gynecol Oncol. 2005 Apr;97(1):142-50. doi: 10.1016/j.ygyno.2004.12.034. Gynecol Oncol. 2005. PMID: 15790450

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

57 results

Search Page